Objective: Plakoglobin (Pg) is the only cytoplasmic protein component common to both junctional complexes mediating cell±cell adhesion, adherens junctions and desmosomes. In these complexes Pg appears to act as a linker protein anchoring transmembrane proteins of the cadherin superfamily to the actin cytoskeleton and intermediate ®lament system respectively. Intercellular adhesion is frequently disturbed in skin diseases and in carcinomas, enabling tumour progression and metastasis. Whereas Pg expression is lost in some thyroid tumours and carcinoma cell lines, little information on Pg gene regulation is currently available owing to a lack of promoter studies. Design and methods: We have cloned and sequenced genomic DNA from a human library that resulted in 979 bp upstream of the published Pg cDNA. The transcriptional start was mapped by rapid ampli®cation of cDNA ends. Methylation-speci®c PCR of bisul®te-modi®ed cell line DNA was applied to probe the methylation status of a promoter-associated CpG island. Reporter-gene constructs of various promoter fragments were transiently transfected in thyroid carcinoma cell lines and their activities were determined by luciferase measurements. Results and conclusions: A 1 kb DNA fragment harbouring a functional promoter of the human Pg gene was cloned and characterized. The sequence lacks a canonical TATA box, but contains putative CCAAT boxes as well as various putative binding sites for transcription factors, among them SP1 and AP2, proximal to the transcriptional start. Considerable promoter activity was found in thyroid cell lines and deletion analysis indicated that a 300 bp region proximal to the 5 H -untranslated region of the mRNA represents the minimal promoter of the human Pg gene. As cells lacking endogenous Pg expression were found to contain methylated CpG dinucleotides in a CpG island located around the transcriptional start site, it is suggested that epigenetic mechanisms such as DNA methylation contribute to dysregulated Pg expression.
Introduction
Plakoglobin (Pg), also termed g-catenin, forms with its closest relatives b-catenin and Drosophila segment polarity protein, armadillo, a subgroup of the large armadillo protein family that share a 42-amino-acid motif repeated several times (1) . As a major cytoplasmic protein, Pg occurs in a soluble and a membraneassociated form, where it was ®rst identi®ed in both adhesive intercellular junctions, desmosomes and adherens junctions (2, 3) . In adherens junctions, Pg and bcatenin form mutually exclusive complexes with the cytoplasmic tail of E-cadherin and provide a link to a-catenin that, in turn, establishes a connection to actin, which is a prerequisite for stable cadherin-mediated cell adhesion to occur (4) . Pg, unlike the other catenins, is in addition a major component of the desmosomal plaque (2) where it binds to the desmosomal cadherins, desmogleins and desmocollins, to anchor them through desmoplakins to the intermediate ®lament (5) . The crucial roles of Pg for protein sorting, desmosomal plaque assembly and intermediate ®lament anchorage have clearly been demonstrated with Pg null-mutant mouse embryos that die early during development as a result of severe heart defects (6, 7) . Recently, a homozygous mutation of the Pg gene leading to a truncation of the protein has been identi®ed in patients suffering from Naxos disease, an autosomal recessive form of arrhythmogenic right ventricular cardiomyopathy (8) . Even though Pg is an important common component of both cell±cell adhesion complexes, which are essential for tissue integrity and are frequently negatively affected in invasive and metastatic carcinomas (4), the gene structure has only very recently been published (9) , and factors regulating its promoter are still unknown. Previously, we and others observed a decreased expression of Pg in thyroid carcinomas and cell lines, which could partially be restored by inhibition of DNA methylation (10±14). To better understand regulation of the gene encoding Pg, we cloned the 5 Hanking region of the human Pg gene, characterized its activity by transient transfection analysis in thyroid carcinoma cell lines and investigated the DNA methylation status of an associated CpG island.
Materials and methods

Cloning and sequence analysis
To clone the promoter region of the human Pg gene, ®ve human DNA libraries of the Genome Walker kit (Clontech, Heidelberg, Germany) were used. Each library consists of uncloned, restriction enzymedigested, adaptor-ligated genomic DNA fragments. PCR was performed with each of the libraries with the adaptor-speci®c primer AP1 and the Pg-speci®c reverse primer 1 (5 H -GGTGGGAGCCGGCGCGGACAGC-3
H ; start at position 69 in Pg cDNA, accession no. M23410). Following dilution, the products were used as templates for a second PCR with nested adaptor primer AP2 and Pg-speci®c reverse primer 2 (5 H -GAACTGAGCTCGGCGCGGTCGGG-3
H ; start at position 47 in Pg cDNA). Ampli®cation conditions were as described in the manufacturers protocol and Tth polymerase mixes as well as other reagent components were also obtained from Clontech. An ampli®ed DNA fragment of 0.7 kbp obtained from the ScaI library was cloned in the T/A cloning vector pCRII (Invitrogen, Leek, The Netherlands) and designated pPG1.
DNA sequencing was performed on both strands using the Thermo sequenase radiolabeled terminator cycle sequencing kit (Amersham Life Sciences, Freiburg, Germany). To further extend the obtained sequence a second PCR walk was performed as before but using primer pairs AP1/Pg3 (5 H -ACAGACGCCTT-CACCGGCCAGCCAAC-3 H ) and AP2/Pg4 (5 H -TCAGCGT-CAGGCATGATGCTTCTTTGGGCT-3 H ) in the ®rst and second PCR respectively, whereby the Pg-speci®c primers were derived from the pPG1-upstream sequence. As before, the product was cloned to give pPG2, subsequently sequenced, and the complete sequence assembled.
Nucleotide homology searches were performed using the Fasta3 program (15) (http://www.ebi.ac.uk/fasta3) and searches for potential transcription factor sites were carried out with the programs Mathinspector 2.2 (16) and FunsiteP (17) (both at http://transfac.gbf.de/ transfac/programs) using the TRANSFAC database (18) . The programs Grail 1.3 (http://compbio.ornl. gov/grail-1.3) and CpGplot/report (http://www.ebi. ac.uk/emboss/cpgplot) were used for CpG island prediction.
5
H -Rapid ampli®cation of cDNA ends
To characterize the transcriptional start an established 5 H -rapid ampli®cation of cDNA ends (5 H -RACE) procedure (19) was applied using a commercial kit (Gibco Life Technologies, Eggenstein, Germany) according to the manufacturers instructions. Brie¯y, 3 mg total RNA isolated from 8505C cells was reverse transcribed by Superscript RT II (Gibco Life Technologies) in separate reactions using the Pg-speci®c antisense primers 361R (5
The cDNAs were treated with RNase H, puri®ed and dC-tailed in a terminal transferase reaction. Primary PCR was performed with abridged anchor primer and the Pg-speci®c nested primers 203R or 174R (5-TCTGCTGCCACTCAGTCACCT-3 H ). Following secondary PCR using universal abridged anchor primer and Pg-speci®c nested primers 174R or 141R (5-CCATCAGGTTCATCACCTCCAT-3 H ) the respective PCR products were subcloned in pCR2.1 (Invitrogen) and the corresponding nucleotide sequences of a total of 15 clones were determined by didesoxy sequencing using primer 141R and universal M13 primers.
Reporter-gene constructs
For in vitro transient expression assays a number of fragments were subcloned into the SmaI site of the promoter-and enhancerless luciferase (LUC) expression vector pGL3Basic (Promega, Mannheim, Germany).
In brief, the cloned fragment was cut from pPG1 with EcoRI, the ends ®lled in with Klenow DNA polymerase and the resulting fragment cloned in both orientations in the SmaI site in front of the LUC gene of pGL3Basic yielding constructs pGLPg1 and pGLPg2 (reverse orientation). Using unique SmaI sites in the fragment and the adaptor, pGLPg1 and pGLPg2 were digested with SmaI, the inserts removed and the vectors religated to give the deletion constructs pGLPg3 and pGLPg4 (reverse orientation). The dissected SmaI fragment of this step (,400 bp) distal to the coding region was subcloned in SmaI-digested pGL3Basic, yielding the constructs pGLPg5 and pGLPg6 (reverse orientation). The EcoRI fragment isolated from pPG1 was further cut with BspMI. Products of 0.24 kbp and 0.44 bp were isolated, their ends ®lled and cloned in SmaI-digested pGL3Basic, and named pGLPg7 and pPLPg9 respectively. The corresponding constructs with DNA fragments in reverse orientation were termed pPGLPg8 and pGLPg10 respectively. Two DNA fragments ending proximal to the 5 H -end of the published Pg cDNA were produced by PCR using pPG1 as template and a common reverse primer 5
H -AAGGCAG-CAACTCAGTAACG-3 H in combination with forward primers 5 H -GTTAGGATGAGACCTCAAG-3
H . Both products were cloned in pCR2.1 (Invitrogen, Karlsruhe, Germany) using a T/A cloning kit and as before their respective EcoRI fragments were ®lled in and subcloned into the SmaI site of pGL3Basic to give transfection constructs pGLPg11 and pGLPg12 respectively. The orientations of cloned fragments were checked by restriction enzyme digestions and all constructs were sequenced.
A complete fragment of approximately 1 kbp consisting of PG1 and PG2 was produced by PCR using human genomic DNA and cloned in pCR2.1 (Invitrogen). Thereof, an EcoRV/SmaI-fragment was isolated harbouring PG2 and a part of PG1 and subcloned in the SmaI site of pGLPg5 to yield pGLPg0. Three pGLPg0 clones were sequenced and used for transfections.
Cell culture, transient transfections and promoter activity measurements
Human thyroid carcinoma cell lines FTC-133 (20) (a generous gift from P. E. Goretzki, Du È sseldorf, FRG), C643 (21) (generously supplied by N. E. Heldin, Uppsala, Sweden) and TPC-1 (22) (from S. Jhiang, Columbus, OH, USA) were cultured in DMEM/HamF12 (1:1) supplemented with 10% foetal bovine serum, penicillin (100 IU/ml) and streptomycin (100 mg/ml) at 37 8C in a humidi®ed atmosphere with 5% CO 2 . The human thyroid carcinoma cell line 8505C (23) (DSMZ, Braunschweig, Germany) was grown in RPMI 1640 with supplementations as above. Cells 2 Â 10 5 were plated in six-well plates 1 day before transfection. Transfections mediated by Fugene 6 (Roche, Mannheim, Germany) were carried out according to the manufacturers protocol using 1.5 mg of each promoter construct. To correct for transfection ef®ciency differences 1.5 mg b-galactosidase expression plasmid pSVbGal was cotransfected. The vector pGL3Ctrl (Promega, Mannheim, Germany) served as a positive control in parallel transfections conferring strong LUC expression driven by the SV40 promoter. Enzyme activities were determined 48 h post-transfection using a LUC assay kit and a b-galactosidase assay kit (both from Promega). All LUC activities were normalized to b-galactosidase activity and were given relative to the basal activity of empty pGL3Basic, which was set to unity. Measurements were performed in duplicate and repeated in 3±8 independent experiments. The data shown represent mean values (^s.e.m).
Methylation analysis
To detect DNA hypermethylation of the Pg gene the methylation-speci®c PCR protocol was used (24) . Brie¯y, genomic DNA of cell lines was isolated using a commercial kit (Qiagen, Hilden, FRG) and 1 mg was treated with sodium bisul®te as described (25 Ampli®cation was carried out after an initial enzyme activation step (5 min at 95 8C) for 40 cycles (30 s at 95 8C, 45 sec annealing, 30 s at 72 8C), followed by a ®nal extension (5 min at 72 8C). Annealing temperatures of 62 8C and 60 8C were used for PG-M and PG-U reactions respectively. The PCR products were resolved on a 6% polyacrylamide gel, stained by ethidium bromide and visualized under ultraviolet illumination. Expected PCR product sizes are 76 bp (position +30 to +105; cf. Fig. 1 ) in the case of presence of methylated CpGs in the Pg gene region covered by the PG-M primers or 84 bp (position +24 to +107; cf. Fig. 1 ) in the case of presence of unmethylated CpG dinucleotides using the PG-U primers.
Protein extraction and Western blotting
Cell lines were treated in parallel with and without 5-Aza-2 H -deoxycytidine (AzaC; Sigma Chemicals, Taufkirchen, Germany) at a ®nal concentration of 1 mM in growth medium for 4±5 days. For total protein extract preparations cells were brie¯y washed with phopshate-buffered saline (PBS; 150 mM NaCl, 10 mM sodium phosphate pH 7.4) and lysed by addition of hot Laemmli sample buffer (26) . The lysates were brie¯y sonicated, heated (5 min, 95 8C) and centrifuged (10 min 14 000 Â g to remove insoluble material. The resulting supernatants were used for Western blotting. Protein contents were estimated according to Lowry (27) following trichloroacetic acid precipitation. Equal amounts of protein (10 mg/lane) were separated by 7.5% SDS-PAGE (26) and transferred electrophoretically to polyvinylidene di¯uoride membranes (28) . After blocking with 5% non-fat dry milk in 0.1% Tween/PBS the membranes were incubated overnight at 4 8C with mouse monoclonal antibodies against b-catenin or Pg (Transduction Lab, Lexington, KY, USA). Following incubation with secondary anti-mouse IgG conjugated to either horseradish peroxidase or alkaline phosphatase bands were detected by chemoluminescence using an ECL kit (Amersham) or CSPD plus Emerald-Enhancer (Oncogene Science, San Diego, CA, USA) respectively, according to the manufacturers' protocols.
Results
A PCR-based approach was used to clone the 5 Hanking region of the human Pg gene. The assembled sequence consists of 1026 nucleotides (Fig. 1) H -¯anking region of the human Pg gene (Fig. 1 ) has been deposited with the EMBL Nucleotide Sequence Databases (accession no. AJ276892). Whereas the overall GC-content of the sequence is 50%, the GC-content of 300 bp located at the 3 H -end is considerably higher (66%) and this short segment notably harbours 24 out of a total 31 CpG dinucleotides. According to established criteria (29) computer analysis by the CpGplot program predicts one CpG island of at least 330 bp that starts at position 2219 ( Fig. 1 ) and extends into exon 1 of the Pg gene. The promoter sequence lacks a canonical TATA box, but contains four putative CCAAT boxes, of which the most downstream CCAAT box located 200 bp proximal to the start of the corresponding Pg cDNA shows the least differences in the¯anking nucleotides to published CCAAT consensus sequences (30, 31) . Computer searches for putative regulatory regions resulted in a number of probable transcription factor binding sites, most of them localize to the second half of the sequence. Putative regulatory factors include stimulatory protein-1 (SP1), activator protein-2 (AP2), PEA3, MyoD and Nkx2.5 (Fig. 1) .
The transcriptional site was mapped by the 5 H -RACE procedure (19) using RNA isolated from 8505C, a human anaplastic thyroid carcinoma cell line (23) , and different combinations of Pg mRNA-speci®c primers. Four of 15 sequenced clones extended the Pg cDNA sequence by 14 nucleotides (designated position +1 in Fig. 1 ), four clones started at position +2, and six started in pos. +15, the published 5 H -end of Pg cDNA (3), with the remaining clones being scattered between these regions or were shorter probably due to degradation. On the basis of these results, we assigned two major transcriptional start points at positions +1/+2 and +15 (cf. Fig. 1) .
To study the promoter activity the complete 1026 bp fragment as well as seven deletion fragments were H -RACE and numbering refers to the most distal transcriptional start point (+1). The sequence in italics represents the overlap with the published human plakoglobin cDNA (3), which starts at 2119 relative to the translational start codon. Putative CCAAT boxes are shown underlined and putative regulatory elements are indicated in bold letters above the underlined sequence.
cloned into the promoterless LUC expression vector pGL3Basic. The reporter-gene vectors (cf. Fig. 2A) were used for transient transfections of 8505C cells, and the transcriptional activation was determined by LUC activity measurements. As shown in Fig. 2B , the complete sequence (pGLPg0) was able to ef®ciently drive LUC expression, about 96-fold compared with the empty pGL3Basic vector. Comparison of the data for the full-length construct (pGLPg0) and the 5 H -deletion constructs (pGLPg1, 5 and 9) indicates the presence of a silencing element in the ®rst 360 nucleotides (positions 2965 to 2594). Constructs lacking this 5 Hregion, but cloned in reverse orientation displayed either no or reduced stimulation of LUC expression (Fig. 2B) . These results thus con®rmed that the DNA region 2593 to +61 functions as a promoter element. The central third of the complete sequence (nucleotides 2593 to about 2220; pGLPg3, pGLPg7) did not H -¯anking region of the human Pg gene in front of the LUC gene, or 1.5 mg empty pGL3Basic, and 1.5 mg pSVbGal vector respectively. Expression vectors carrying the respective fragment in antisense orientation were available for pGLPg-constructs 1, 3, 5, 7 and 9. All LUC activities were measured 48 h post-transfection, and were normalized to the b-galactosidase activity. The LUC activity of empty pGL3Basic was set to unity and the activity of each promoter construct was expressed as a fold increase over that value. (C) Cell lines FTC-133, 8505C and TPC-1 were transiently transfected with empty pGL3Basic vector or Pg-LUC constructs pGLPg0, 1, 5 or 11 in combination with pSVbGal and activity measurements were performed as in Fig. 2B. stimulate LUC transcription ef®ciently when used without the last part indicating essential functions of the latter region. The high LUC activity (about 140-fold when compared with basal activity of pGL3Basic) measured with fragments harbouring the 3 H -end regions (pGLPg9, pGLPg5) is consistent with this interpretation. Thus, most of the promoter activity can be attributed exclusively to the last third of the sequence (nucleotides about 2220 to +61). Further 5 Hdeletions led to a progressive decrease of LUC activity (pGLPg11, pGLPg12). Notably, only in these two constructs have the 46 nucleotides corresponding to the 5 H -UTR of the Pg mRNA also been deleted. Obviously this GC-rich region positively regulates transcription, as indicated by the threefold lower stimulation of LUC expression by construct pGLPg11 when compared with the otherwise similar construct, pGLPg5 (Fig. 2B) . Further deletion of regions harbouring the most downstream CCAAT box and GC-rich regions, probably representing binding sites for SP1 and AP2, considerably decreased LUC expression (pGLPG12).
In order to better understand the variable downregulation of Pg expression in different thyroid tumours and cell lines reported previously (10±14), we used four constructs (pGLPg0, 1, 5 and 11) for transient transfections of three human thyroid carcinoma cell lines (FTC-133, TPC-1 and 8505C) which endogenously express very low, medium and high levels of Pg (Fig. 3A) respectively and were derived from follicular, papillary and anaplastic thyroid tumours respectively (20, 22, 23) . The overall activity patterns of transfected constructs were comparable in the three cell lines (Fig. 2C) . Again a lower LUC expression of the the fulllenght construct (pGLPg0) compared with the 5 Hdeletion constructs lacking the ®rst 360 nucleotides (pGLPg1 and 5) may be attributed to the presence of a silencing element in that region. As well, the strongly decreased LUC activity of construct pGLPg11 might again be indicative of a regulatory role of the 5 H -UTR of Pg. The results with all constructs also indicate, that a loss of Pg expression in FTC-133 and TPC-1 is not caused by the lack of essential transcription factors, as transfectants displayed considerable LUC activity (TPC-1) compared with transfected 8505C, or even approximately twofold higher LUC activity in the case of FTC133, that has almost completely lost Pg expression.
To identify an underlying mechanism for loss of Pg, cell lines including C643, an anaplastic thyroid carcinoma cell (21) , were treated with the wellknown cytosine analog AzaC, which after being incorporated into DNA inhibits DNA (cytosine-5)-methyltransferase at the target site for DNA methylation, CpG dinucleotides, and thereby indirectly leads to demethylation of methylated CpG islands (32) . A partial restoration of Pg expression was detectable in FTC133 and C643 by Western blotting (Fig. 3A) as well as by Northern blotting (data not shown). The AzaCmediated increase of Pg gene expression appears to be speci®c as the amounts of b-catenin (Fig. 3A) , acatenin and p120
ctn (data not shown) remain unaffected. Therefore, Pg down-regulation might result directly from aberrant DNA hypermethylation of its gene. To investigate this possibility, genomic DNA of cell lines was modi®ed by bisul®te treatment, which converts unmethylated cytosine residues to uracil without affecting 5-Methylcytosine residues, and subsequently subjected to PCR with primer pairs PG-M and PG-U intended to discriminate the methylation status of CpG dinucleotides located to the CpG island extending into exon 1. As shown in Fig. 3B, 8505C and TPC-1, which both were AzaC-unresponsive and endogenously express Pg, contain only unmethylated alleles. By contrast, the Pg-negative and AzaC-responsive FTC133 and C643 clearly displayed CpG methylation in addition to unmethylated alleles.
Discussion
The present study reports the cloning and characterization of a 1 kb DNA region representing the human Pg promoter region, which to our knowledge has not yet been published. In previous investigations the human Pg cDNA was cloned (3), and the human Pg gene was mapped to chromosome 17q12-q22 in proximity to the breast cancer susceptibility gene 1, BRCA1 (33) . Very recently, when this work was ®nished, the complete genomic organization of the human Pg gene has been reported showing that the Pg gene probably consists of 13 exons covering a 17 kb-long DNA region (9) . The start region of the sequence obtained (accession no. AF233882) is identical with our nucleotide sequence, but did not cover the ®rst 152 nucleotides, as reported here. In addition, a working draft sequence generated from a chromosome 17-derived clone in the course of the human genome project became accessible in the EMBL HTG nucleotide database (accession no. AC012192) which at present (version 14) consists of 183 kb DNA in 15 unordered contigs; a part of contig 45 was found to be identical (99.8%) to the DNA sequence reported here and extends our sequence in both directions. In agreement with our data, both sequences show the same nucleotide difference at the start position of the published Pg cDNA sequence (pos. +15 in Fig. 1 ; G instead of a C).
These data clearly con®rm that we achieved the cloning of a part of a functional human Pg promoter. In contrast to the gene encoding the related b-catenin (34) no obvious TATA box is present, but the cloned region includes in the 3 H -half CCAAT boxes, GC-rich regions, the presence of putative transcription factor binding sites, and a high frequency of CpG dinucleotides located to a CpG island, which in combination are characteristic features commonly found in many promoters of housekeeping and tissue-speci®c genes (29±31).
Two closely neighboured major transcriptional start sites of the Pg gene were mapped by 5 H -RACE their positions are compatible with the results of the transfection experiments (cf. Fig. 2 ) and the location of the most proximal CCAAT box (position 2193, cf. Fig. 1 ), although the latter is more frequently found at ,position 270 in promoters lacking TATA boxes (30) . Transfection of thyroid cell lines with Pg reporter-gene constructs results in a strong transcriptional activation that depends both on orientation and size of the respective fragments. Although a direct participation of trans-acting factors remains to be shown, the major CCAAT box-binding protein, NF-Y (30), as well as the general transcriptional activators, AP2 and SP1, binding to GC-rich regions following the proximal CCAAT box might contribute to the transcriptional activation observed.
Because of its comparable roles in adherens junctions and desmosomes Pg is commonly found in epithelia of various tissues but its expression is not restricted to them (5) . Essential functions of Pg for heart development which can not be compensated for by its homologoue, b-catenin have been revealed in studies with knockout mice (6, 7) . Interestingly, a sequence element (position 2645; cf. Fig. 1 ) could represent a binding site for a heart-speci®c transcription factor, termed Nkx2.5 (also called Csx), a homeobox-containing gene expressed in cardiocytes and their progenitors and found to be essential for cardiac development (35, 36) . As two additional Nkx2.5 binding sites are present in a region located further upstream, covered by the sequence AC012192 (see above), it is tempting to speculate that the Pg gene represents a downstream target for Nkx2.5 in the heart.
Loss of cadherin/catenin-dependent intercellular adhesion is found frequently in many carcinomas and represents one key step in tumour progression and metastasis (4) . Pg as an essential cytoplasmic anchoring protein for classic cadherins (e.g. E-cadherin) in adherens junctions and demosomal cadherins (desmogleins and desmocollins) in desmosomes participates in these processes. Reduced Pg expression correlates with malignant transformation in certain tumour cell lines (10, 12, 37, 38) and Pg overexpression can decrease the tumorigenicity and proliferation of transformed cells (39, 40) . This might also relate to the participation of Pg and b-catenin in the wnt signal transduction pathway that is frequently dysregulated in certain carcinomas (41) . Whereas the Pg-related b-catenin represents a potential oncogene, Pg appears to play a tumour suppressor role (33, 39, 40) . Even though the contribution of dysregulated Pg expression to thyrocyte transformation and thyroid carcinoma progression is unknown at present, studies in differentiated and anaplastic thyroid carcinoma tissues (11, 14, 42) and in cell culture models (10, 12, 13) demonstrated frequent loss of Pg, in part along with de-differentiation. Mechanisms are mostly unknown so far and could include gene mutations/deletions, altered RNA or protein stability, hormonal dysregulation, loss/overexpression of transcriptional regulators and epigenetic silencing. This study addressed the latter two mechanisms. First, comparison of reporter-gene activity in different cell lines (cf. Fig. 2C ) shows no obvious correlation to the endogenous Pg levels, making it unlikely that lack of essential transcription factors plays a role. The data indicate that a silencing element may reside in the ®rst 360 nucleotides of the promoter. In addition, a putative binding site for MyoD (position 2375) might be shared by the transcription factor Snail, that has recently been shown to down-regulate E-cadherin expression in tumour cells (43, 44) and may in another cellular context be involved in Pg gene regulation. Second, in accordance with previous investigations (10, 12) AzaC-mediated DNA demethylation leads to partial restoration of Pg expression in Pgnegative thyroid carcinoma cell lines. The cloning of the Pg promotor region enabled us to identify an associated CpG island, and to demonstrate by methylation-speci®c PCR that Pg gene methylation around the start point of transcription is involved in Pg gene silencing in thyroid carcinoma cell lines. This is the ®rst report concerning epigenetic regulation of the Pg gene. Whether these mechanisms are involved in the downregulation of the Pg gene expression during tumour formation in the thyroid, as was shown for the Ecadherin gene (45) , has to be investigated in future studies analysing thyroid tumour biopsies.
In summary, we have cloned the 5 H -¯anking region of the human Pg gene, characterized its promoter activity in thyroid cell lines and have identi®ed promoter hypermethylation as a mechanism that participates to Pg expression. Further work is required to de®ne the interaction of suggested factors contributing to the regulation of this important gene as well as a detailed analysis of the methylation pattern in carcinoma tissues, which will assist in tumour pro®ling.
